Pharmaceutical risk-sharing arrangements (RSAs) pose an alternative option to the traditional fixed-price methods and are intended to align the price of medication with the value delivered in treating patients, balancing clinical need with affordability in situations where uncertainties over a certain medicine are present.

This study provides an example on how to set up a systematic, traceable, and transparent methodology for the design and implementation of RSAs.

This study could inform other policy makers willing to set up a RSA methodology in their geographies, or provide new ideas for existing RSA processes.